Identification of genes correlated with early-stage bladder cancer progression

Cancer Prevention Research

Volumn 3, Issue 6, 2010, Pages 776-786

  Stone II, Randolph ^a   Sabichi, Anita L ^c   Gill, Jennifer ^a   Lee, I Ling ^c   Adegboyega, Patrick ^a   Dai, Michael S ^a   Loganantharaj, Raja ^d   Trutschl, Marjan ^b   Cvek, Urska ^b   Clifford, John L ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF LOUISIANA AT LAFAYETTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CELL CYCLE PROTEIN; MESSENGER RNA; RNA; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER INCIDENCE; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA MICROARRAY; GENE CONTROL; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC ASSOCIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; UROTHELIUM; ANIMAL; BIOSYNTHESIS; BLADDER DISEASE; BLADDER TUMOR; CARCINOMA IN SITU; DISEASE COURSE; DISEASE MODEL; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; GENETICS; HUMAN; HYPERPLASIA; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PRECANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; TUMOR GENE;

ANIMALS; CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; CELL CYCLE PROTEINS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENES, NEOPLASM; HUMANS; HYPERPLASIA; MAGNETIC RESONANCE IMAGING; MICE; MICE, TRANSGENIC; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRECANCEROUS CONDITIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; URINARY BLADDER DISEASES; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 77953502572     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0189     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-45.
2. Prout GR, Jr. Bladder carcinoma and a TNM system of classification. J Urol 1977;117:583-90.
3. Budman LI, Kassouf W, Steinberg JR. Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J 2008;2:212-21.
4. Konety B, Lotan Y. Urothelial bladder cancer: biomarkers for detection and screening. BJU Int 2008;102:1234-41.
5. Bostwick DG, Ramnani D, Cheng L. Diagnosis and grading of bladder cancer and associated lesions. Urol Clin North Am 1999;26:493-507. (Pubitemid 29411681)
6. Sabichi AL, Lerner SP, Grossman HB, Lippman SM. Retinoids in the chemoprevention of bladder cancer. Curr Opin Oncol 1998;10:479-84.
7. Zhang ZT, Pak J, Shapiro E, Sun TT, Wu XR. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res 1999;59:3512-7.
8. Ahuja D, Saenz-Robles MT, Pipas JM. SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene 2005;24:7729-45.
9. Cordon-Cardo C, Zhang ZF, Dalbagni G, et al. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 1997;57:1217-21.
10. Dimova DK, Dyson NJ. The E2F transcriptional network: old acquaintances with new faces. Oncogene 2005;24:2810-26.
11. Lodde M, Fradet Y. The detection of genetic markers of bladder cancer in urine and serum. Curr Opin Urol 2008;18:499-503.
12. Lam T, Nabi G. Potential of urinary biomarkers in early bladder cancer diagnosis. Expert Rev Anticancer Ther 2007;7:1105-15.
13. Shariat SF, Karakiewicz PI, Ashfaq R, et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 2008;112:315-25.
14. Harris LD, De La Cerda J, Tuziak T, et al. Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray. Mol Carcinog 2008;47:678-85.
15. Alvarez A, Lokeshwar VB. Bladder cancer biomarkers: current developments and future implementation. Curr Opin Urol 2007;17:341-6.
16. Foundation RR Developmental Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for statistical computing; 2007.
17. Clifford J, Chiba H, Sobieszczuk D, Metzger D, Chambon P. RXRα-null F9 embryonal carcinoma cells are resistant to the differentiation, anti-proliferative and apoptotic effects of retinoids. Embo J 1996;15:4142-55.
18. Xu H, Cheepala S, McCauley E, et al. Chemoprevention of skin carcinogenesis by phenylretinamides: retinoid receptor-independent tumor suppression. Clin Cancer Res 2006;12:969-79.
19. Clifford JL, Sabichi AL, Zou C, et al. Effects of novel phenylretinamides on cell growth and apoptosis in bladder cancer. Cancer Epidemiol Biomarkers Prev 2001;10:391-5.
20. Deeb KK, Michalowska AM, Yoon CY, et al. Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis. Cancer Res 2007;67:8065-80.
21. Sabichi A, Keyhani A, Tanaka N, et al. Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression. J Urol 2006;175:1133-7.
22. Kong QY, Liu J, Chen XY, Wang XW, Sun Y, Li H. Differential expression patterns of hyaluronan receptors CD44 and RHAMM in transitional cell carcinomas of urinary bladder. Oncol Rep 2003;10:51-5.
23. Inagaki T, Ebisuno S, Uekado Y, et al. PCNA and p53 in urinary bladder cancer: correlation with histological findings and prognosis. Int J Urol 1997;4:172-7.
24. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007;26:3279-90.
25. Angel P, Szabowski A, Schorpp-Kistner M. Function and regulation of AP-1 subunits in skin physiology and pathology. Oncogene 2001;20:2413-23.
26. Frost JA, Geppert TD, Cobb MH, Feramisco JR. A requirement for extracellular signal-regulated kinase (ERK) function in the activation of AP-1 by Ha-Ras, phorbol 12-myristate 13-acetate, and serum. Proc Natl Acad Sci U S A 1994;91:3844-8.
27. Watts RG, Huang C, Young MR, et al. Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation. Oncogene 1998;17:3493-8.
28. Niles RM. Signaling pathways in retinoid chemoprevention and treatment of cancer. Mutat Res 2004;555:81-96.
29. Cheepala SB, Yin W, Syed Z, et al. Identification of the B-Raf/Mek/ Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotion. Mol Cancer 2009;8:27.
30. Cheepala SB, Syed Z, Trutschl M, Cvek U, Clifford JL. Retinoids and skin: microarrays shed new light on chemopreventive action of alltrans retinoic acid. Mol Carcinog 2007;46:634-9.
31. Korman HJ, Peabody JO, Cerny JC, Farah RN, Yao J, Raz A. Autocrine motility factor receptor as a possible urine marker for transitional cell carcinoma of the bladder. J Urol 1996;155:347-9.